David Amsellem
Stock Analyst at Piper Sandler
(4.65)
# 178
Out of 4,940 analysts
148
Total ratings
60.17%
Success rate
20.34%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $30 → $25 | $27.36 | -8.63% | 9 | Aug 8, 2025 | |
| CORT Corcept Therapeutics | Maintains: Overweight | $131 → $121 | $71.97 | +68.13% | 8 | Aug 1, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $154 → $175 | $123.99 | +41.14% | 11 | Jul 31, 2025 | |
| AMGN Amgen | Reiterates: Overweight | $328 | $285.09 | +15.05% | 4 | Jun 27, 2025 | |
| BIIB Biogen | Reiterates: Neutral | $115 | $128.00 | -10.16% | 1 | Jun 12, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $24 → $18 | $9.01 | +99.78% | 6 | May 15, 2025 | |
| COLL Collegium Pharmaceutical | Reiterates: Neutral | $36 → $37 | $36.14 | +2.38% | 8 | May 9, 2025 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $176 → $147 | $110.75 | +32.73% | 14 | May 7, 2025 | |
| BMY Bristol-Myers Squibb Company | Initiates: Overweight | $65 | $45.93 | +41.52% | 1 | Apr 22, 2025 | |
| XERS Xeris Biopharma Holdings | Reiterates: Neutral | $3 → $4 | $7.20 | -44.44% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $13 | $22.29 | -41.68% | 5 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $10 | $9.86 | +1.42% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $30 | $16.42 | +82.70% | 10 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $13 | $12.79 | +1.64% | 5 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $11 | $8.84 | +24.43% | 4 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $38 → $37 | $26.54 | +39.41% | 7 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $84.88 | -19.89% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $41 → $36 | $40.51 | -11.13% | 15 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $6.66 | -54.95% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $25.20 | +66.67% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $3.86 | +159.07% | 1 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $0.84 | +2,411.06% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $113 | $103.96 | +8.70% | 3 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $34.80 | +20.69% | 3 | Oct 16, 2023 |
Amphastar Pharmaceuticals
Aug 8, 2025
Maintains: Neutral
Price Target: $30 → $25
Current: $27.36
Upside: -8.63%
Corcept Therapeutics
Aug 1, 2025
Maintains: Overweight
Price Target: $131 → $121
Current: $71.97
Upside: +68.13%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Overweight
Price Target: $154 → $175
Current: $123.99
Upside: +41.14%
Amgen
Jun 27, 2025
Reiterates: Overweight
Price Target: $328
Current: $285.09
Upside: +15.05%
Biogen
Jun 12, 2025
Reiterates: Neutral
Price Target: $115
Current: $128.00
Upside: -10.16%
Organon & Co.
May 15, 2025
Maintains: Overweight
Price Target: $24 → $18
Current: $9.01
Upside: +99.78%
Collegium Pharmaceutical
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $36.14
Upside: +2.38%
Jazz Pharmaceuticals
May 7, 2025
Reiterates: Overweight
Price Target: $176 → $147
Current: $110.75
Upside: +32.73%
Bristol-Myers Squibb Company
Apr 22, 2025
Initiates: Overweight
Price Target: $65
Current: $45.93
Upside: +41.52%
Xeris Biopharma Holdings
Mar 7, 2025
Reiterates: Neutral
Price Target: $3 → $4
Current: $7.20
Upside: -44.44%
Mar 6, 2025
Maintains: Overweight
Price Target: $16 → $13
Current: $22.29
Upside: -41.68%
Mar 5, 2025
Reiterates: Neutral
Price Target: $14 → $10
Current: $9.86
Upside: +1.42%
Jan 17, 2025
Maintains: Overweight
Price Target: $23 → $30
Current: $16.42
Upside: +82.70%
Jan 10, 2025
Maintains: Overweight
Price Target: $24 → $13
Current: $12.79
Upside: +1.64%
Nov 11, 2024
Maintains: Overweight
Price Target: $9 → $11
Current: $8.84
Upside: +24.43%
Oct 25, 2024
Reiterates: Overweight
Price Target: $38 → $37
Current: $26.54
Upside: +39.41%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $84.88
Upside: -19.89%
Sep 11, 2024
Downgrades: Neutral
Price Target: $41 → $36
Current: $40.51
Upside: -11.13%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $6.66
Upside: -54.95%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $25.20
Upside: +66.67%
Apr 11, 2024
Initiates: Overweight
Price Target: $10
Current: $3.86
Upside: +159.07%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $0.84
Upside: +2,411.06%
Jan 16, 2024
Maintains: Overweight
Price Target: $90 → $113
Current: $103.96
Upside: +8.70%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $34.80
Upside: +20.69%